Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL849 (CH 3565, Stri-dex cleansing bar, Triclosan, Tegusept, CH-3565, NSC-759151, DNDI1246774, Triclosan component of colgate total, Innoxa, Skinsan, Aquasept, Gamophen, Manusept, Cloxifenol) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| CBR1/Carbonyl reductase [NADPH] 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5586] [GtoPdb: 1383] [UniProtKB: P16152] | ||||||||
| ChEMBL | Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate | B | 7.22 | pKi | 60 | nM | Ki | Bioorg Med Chem (2009) 17: 530-536 [PMID:19097799] |
| ChEMBL | Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate | B | 6.4 | pIC50 | 400 | nM | IC50 | Bioorg Med Chem (2009) 17: 530-536 [PMID:19097799] |
| heat shock protein family A (Hsp70) member 5/Endoplasmic reticulum chaperone BiP in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1781865] [GtoPdb: 3193] [UniProtKB: P11021] | ||||||||
| ChEMBL | Inhibition of GRP78 (26 to 636 residues) (unknown origin) expressed in Escherichia coli BL21 DE3 cells pre-incubated for 10 mins before FITC-NRLLLTG fluorescent peptide addition in presence of 20 uM ADP followed by further incubation for 2 hrs by fluorescence polarization assay | B | 4 | pIC50 | 100000 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 1689-1693 [PMID:31129054] |
| Enoyl-acyl-carrier protein reductase in Plasmodium falciparum (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4150] [UniProtKB: Q965D5] | ||||||||
| ChEMBL | Inhibition of Plasmodium falciparum recombinant enoyl ACP reductase expressed in BL21 (DE3) cells with respect to crotonyl CoA | B | 6.18 | pKi | 660 | nM | Ki | J Med Chem (2007) 50: 2665-2675 [PMID:17477517] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of butein | B | 7.15 | pKi | 71.02 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGC | B | 7.28 | pKi | 52.71 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum enoyl-acyl carrier protein reductase expressed in Escherichia coli BL21(DE3) by spectrophotometry | B | 7.3 | pKi | 50 | nM | Ki | Eur J Med Chem (2009) 44: 3009-3019 [PMID:19217192] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of quercetin | B | 7.52 | pKi | 30.54 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of ECG | B | 7.55 | pKi | 28.31 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of butein | B | 7.86 | pKi | 13.72 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of quercetin | B | 8 | pKi | 10 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of EGC | B | 8.08 | pKi | 8.25 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of ECG | B | 8.1 | pKi | 8 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGCG | B | 8.14 | pKi | 7.29 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of EGCG | B | 9 | pKi | 1 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of butein by dilution assay | B | 9.1 | pKi | 0.8 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of quercetin by dilution assay | B | 9.55 | pKi | 0.28 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of EGC by dilution assay | B | 9.96 | pKi | 0.11 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR in presence of ECG by dilution assay | B | 10.28 | pKi | 0.05 | nM | Ki | J Med Chem (2007) 50: 765-775 [PMID:17263522] |
| ChEMBL | Inhibition of Plasmodium falciparum Enoyl-ACP reductase using crotonyl-CoA as substrate peincubated for 5 mins measured after 10 mins of substrate addition by UV-vis spectrophotometry | B | 6.7 | pIC50 | 200 | nM | IC50 | J Nat Prod (2011) 74: 1370-1378 [PMID:21619045] |
| ChEMBL | Inhibition of Plasmodium falciparum enoyl-acyl carrier protein reductase | B | 7.14 | pIC50 | 73 | nM | IC50 | Eur J Med Chem (2009) 44: 3009-3019 [PMID:19217192] |
| ChEMBL | Inhibition of PfENR enzymatic activity | B | 7.14 | pIC50 | 73 | nM | IC50 | Bioorg Med Chem Lett (2005) 15: 5247-5252 [PMID:16198563] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR | B | 7.14 | pIC50 | 73 | nM | IC50 | J Biol Chem (2007) 282: 25436-25444 [PMID:17567585] |
| ChEMBL | Inhibition of Plasmodium falciparum ENR enzymatic activity | B | 7.14 | pIC50 | 73 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 2163-2169 [PMID:16466916] |
| ChEMBL | Inhibition of Plasmodium falciparum enoyl-ACP reductase assessed as oxidation of NADH to NAD+ after 10 mins by spectrophotometric analysis | B | 7.15 | pIC50 | 70 | nM | IC50 | Bioorg Med Chem Lett (2012) 22: 610-612 [PMID:22082562] |
| ChEMBL | Inhibition of Plasmodium falciparum recombinant FabI | B | 7.15 | pIC50 | 70 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 2552-2558 [PMID:17485508] |
| ChEMBL | Inhibition of Plasmodium falciparum recombinant enoyl ACP reductase expressed in BL21 (DE3) cells | B | 7.18 | pIC50 | 66 | nM | IC50 | J Med Chem (2007) 50: 2665-2675 [PMID:17477517] |
| Enoyl-(Acyl-carrier-protein) reductase in Streptococcus pneumoniae (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075024] [UniProtKB: Q9FBC5] | ||||||||
| ChEMBL | Inhibition of Streptococcus pneumoniae FabK | B | 4.49 | pIC50 | >32000 | nM | IC50 | J Med Chem (2007) 50: 4710-4720 [PMID:17713898] |
| ChEMBL | Inhibition of Streptococcus pneumoniae enoyl-ACP reductase FabK | B | 4.49 | pIC50 | >32000 | nM | IC50 | Bioorg Med Chem (2007) 15: 7325-7336 [PMID:17892940] |
| Enoyl-[acyl-carrier-protein] reductase [NADH] in Mycobacterium tuberculosis (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1849] [UniProtKB: P9WGR1] | ||||||||
| ChEMBL | Inhibition of Mycobacterium tuberculosis InhA | B | 6.66 | pKi | 220 | nM | Ki | Eur J Med Chem (2018) 146: 318-343 [PMID:29407960] |
| ChEMBL | Inhibition of Mycobacterium tuberculosis H37RV InhA | B | 6.7 | pKi | 200 | nM | Ki | Bioorg Med Chem Lett (2008) 18: 3029-3033 [PMID:18457948] |
| ChEMBL | Uncompetitive inhibition of Mycobacterium tuberculosis InhA using trans-2-dodecenoyl-CoA as substrate in presence of NADH | B | 6.7 | pKi | 200 | nM | Ki | Eur J Med Chem (2018) 146: 318-343 [PMID:29407960] |
| ChEMBL | Inhibition of Mycobacterial tuberculosis ATCC 25618 FabI assessed as measuring NADH consumption rate | B | 6.7 | pKi | 200 | nM | Ki | Eur J Med Chem (2020) 208: 112757-112757 [PMID:32883635] |
| ChEMBL | Binding affinity to Mycobacterium tuberculosis InhA | B | 6.7 | pKi | 200 | nM | Ki | Eur J Med Chem (2018) 150: 525-545 [PMID:29549838] |
| ChEMBL | Inhibition of Mycobacterium tuberculosis InhA using trans-2-decenoyl-N-acetylcysteamine as substrate preincubated for 1 hr followed by substrate addition measured every 30 secs for 5 mins | B | 5 | pIC50 | 10000 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 2084-2090 [PMID:29748048] |
| ChEMBL | Inhibition of recombinant Mycobacterium tuberculosis InhA expressed in Escherichia coli Rosette(DE3) pLysS using trans-2-decenoyl-N-acetylcysteamine as substrate by spectrophotometric method | B | 5.21 | pIC50 | 6140 | nM | IC50 | Bioorg Med Chem (2019) 27: 1509-1516 [PMID:30846404] |
| ChEMBL | inhibition of Mycobacterium tuberculosis InhA after 20 mins by fluorometric assay | B | 5.52 | pIC50 | 3000 | nM | IC50 | J Nat Prod (2002) 65: 1037-1038 [PMID:12141869] |
| ChEMBL | Inhibition of Mycobacterium tuberculosis InhA | B | 6 | pIC50 | 1000 | nM | IC50 | Eur J Med Chem (2018) 146: 318-343 [PMID:29407960] |
| ChEMBL | Inhibition of Mycobacterium tuberculosis InhA using DD-CoA as substrate | B | 6 | pIC50 | 1000 | nM | IC50 | RSC Med Chem (2021) 12: 120-128 [PMID:34046604] |
| ChEMBL | Inhibition of Mycobacterium tuberculosis InhA using dodecyl coA as substrate by LC-MS/MS analysis | B | 6.2 | pIC50 | 630 | nM | IC50 | ACS Med Chem Lett (2014) 5: 1005-1009 [PMID:25221657] |
| ChEMBL | Inhibition of wild type Mycobacterium tuberculosis inhA | B | 6.7 | pIC50 | 200 | nM | IC50 | J Med Chem (2013) 56: 8533-8542 [PMID:24107081] |
| Enoyl-[acyl-carrier-protein] reductase [NADH] in Francisella tularensis subsp. tularensis (strain SCHU S4 / Schu 4) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2150835] [UniProtKB: Q5NGQ3] | ||||||||
| ChEMBL | Inhibition of Francisella tularensis SCHU S4 FabI F93V mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+ | B | 4.85 | pIC50 | 14000 | nM | IC50 | J Med Chem (2013) 56: 5275-5287 [PMID:23815100] |
| ChEMBL | Inhibition of Francisella tularensis SCHU S4 FabI F203L mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+ | B | 5.22 | pIC50 | 6000 | nM | IC50 | J Med Chem (2013) 56: 5275-5287 [PMID:23815100] |
| ChEMBL | Inhibition of C-terminal His6-tagged wild type Francisella tularensis SCHU S4 FabI expressed in Escherichia coli BL21 (DE3) using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+ | B | 5.89 | pIC50 | 1300 | nM | IC50 | J Med Chem (2013) 56: 5275-5287 [PMID:23815100] |
| ChEMBL | Inhibition of Francisella tularensis SCHU S4 FabI R96M mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+ | B | 6.52 | pIC50 | 300 | nM | IC50 | J Med Chem (2013) 56: 5275-5287 [PMID:23815100] |
| ChEMBL | Inhibition of Francisella tularensis SCHU S4 FabI R96G mutant using CrCoA as substrate by UV-vis spectrophotometric analysis in presence of non pre-equilibrated NAD+ | B | 7.3 | pIC50 | 50 | nM | IC50 | J Med Chem (2013) 56: 5275-5287 [PMID:23815100] |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1857] [UniProtKB: P0AEK4] | ||||||||
| ChEMBL | Inhibition of Escherichia coli enoyl-ACP reductase FabI | B | 6.05 | pIC50 | 900 | nM | IC50 | Bioorg Med Chem (2007) 15: 7325-7336 [PMID:17892940] |
| ChEMBL | Antibacterial activity against Escherichia coli FabI | B | 6.37 | pIC50 | 430 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 2241-2244 [PMID:11527706] |
| ChEMBL | Evaluated for inhibition of enoyl acyl carrier protein reductase (FabI) in Escherichia coli. | B | 6.37 | pIC50 | 430 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 2061-2065 [PMID:11514139] |
| ChEMBL | Inhibition of Escherichia coli FabI using crotonoyl-CoA as substrate preincubated for 90 mins | B | 6.77 | pIC50 | 170 | nM | IC50 | J Med Chem (2012) 55: 9914-9928 [PMID:23092194] |
| ChEMBL | Inhibition of Escherichia coli FabI using 2-dodecenoyl-CoA as substrate at pH 8 | B | 8.3 | pIC50 | 5 | nM | IC50 | J Nat Prod (2013) 76: 1064-1070 [PMID:23806111] |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI in Bacillus subtilis (strain 168) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075044] [UniProtKB: P54616] | ||||||||
| ChEMBL | Inhibition of Bacillus anthracis Enoyl ACP reductase | B | 6.3 | pIC50 | 500 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 3565-3569 [PMID:18499454] |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI in S.aureus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3994] [UniProtKB: Q6GI75] | ||||||||
| ChEMBL | Inhibition of Staphylococcus aureus FabI in the presence of NADH using crotonyl CoA as substrate by measuring NADH consumption rate | B | 8.3 | pKi | 5 | nM | Ki | Eur J Med Chem (2020) 208: 112757-112757 [PMID:32883635] |
| ChEMBL | Antibacterial activity against Staphylococcus aureus FabI | B | 5.96 | pIC50 | 1100 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 2241-2244 [PMID:11527706] |
| ChEMBL | Evaluated for inhibition of enoyl acyl carrier protein reductase (FabI) in Staphylococcus aureus. | B | 5.96 | pIC50 | 1100 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 2061-2065 [PMID:11514139] |
| ChEMBL | Inhibition of Staphylococcus aureus FabI assessed as reduction in inhibition of reduction of trans-2-octenoyl N-acetylcysteamine substrate by spectrophotometry | B | 6.36 | pIC50 | 440 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 4481-4486 [PMID:26343826] |
| ChEMBL | Inhibitory activity against Enoyl-ACP reductase FabI in Staphylococcus aureus | B | 7.15 | pIC50 | 70 | nM | IC50 | J Med Chem (2003) 46: 1627-1635 [PMID:12699381] |
| ChEMBL | Concentration required for the 50% inhibition of enoyl-ACP reductase from Staphylococcus aureus was determined. | B | 7.15 | pIC50 | 70 | nM | IC50 | J Med Chem (2002) 45: 3246-3256 [PMID:12109908] |
| ChEMBL | Inhibition of Staphylococcus aureus recombinant FabI using trans-2-octenoyl N-acetylcysteamine thioester as substrate preincubated for 60 mins | B | 7.23 | pIC50 | 59 | nM | IC50 | J Med Chem (2012) 55: 9914-9928 [PMID:23092194] |
| Enoyl-acyl carrier reductase in Toxoplasma gondii (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1250368] [UniProtKB: Q6UCJ9] | ||||||||
| ChEMBL | Inhibition of Toxoplasma gondii enoyl reductase | B | 7.7 | pIC50 | <20 | nM | IC50 | J Med Chem (2010) 53: 6287-6300 [PMID:20698542] |
| ChEMBL | Inhibition of Toxoplasma gondii enoyl reductase assessed as conversion of trans-2-acyl-ACP to acyl-ACP | B | 7.82 | pIC50 | 15 | nM | IC50 | Bioorg Med Chem Lett (2013) 23: 2035-2043 [PMID:23453069] |
| ChEMBL | Inhibition of Toxoplasma gondii enoyl acyl-carrier protein reductase | B | 7.82 | pIC50 | 15 | nM | IC50 | Bioorg Med Chem Lett (2013) 23: 3551-3555 [PMID:23664871] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Antimalarial activity after 48 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake | F | 5.2 | pIC50 | 6258 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Antimalarial activity after 96 hrs against Plasmodium falciparum Dd2 by [3H]hypoxanthine uptake | F | 5.38 | pIC50 | 4186 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Antimalarial activity after 48 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake | F | 5.57 | pIC50 | 2708 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCK2 | F | 5.64 | pIC50 | 2290 | nM | IC50 | Bioorg Med Chem (2008) 16: 5536-5546 [PMID:18434169] |
| ChEMBL | Antimalarial activity after 96 hrs against Plasmodium falciparum GCO3 by [3H]hypoxanthine uptake | F | 5.82 | pIC50 | 1526 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Antiplasmodial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 assessed as growth inhibition after 24 hrs by [3H]-hypoxanthine incorporation assay | F | 5.82 | pIC50 | 1510 | nM | IC50 | J Med Chem (2013) 56: 7516-7526 [PMID:24063369] |
| ChEMBL | Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs | F | 5.92 | pIC50 | 1200 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 307-316 [PMID:17060533] |
| ChEMBL | Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs | F | 5.96 | pIC50 | 1100 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 307-316 [PMID:17060533] |
| ChEMBL | Antiplasmodial activity against asexual blood stage form of Plasmodium falciparum assessed as growth inhibition after 72 hrs by [3H]-hypoxanthine incorporation assay | F | 6 | pIC50 | 1000 | nM | IC50 | J Med Chem (2013) 56: 7516-7526 [PMID:24063369] |
| ChEMBL | Antimalarial activity after 48 hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake | F | 6.11 | pIC50 | 773.9 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Antiparasitic activity against Plasmodium falciparum in RBCs | F | 6.15 | pIC50 | 700 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 2552-2558 [PMID:17485508] |
| ChEMBL | Antimalarial activity after 96hrs against Plasmodium falciparum 7G8 by [3H]hypoxanthine uptake | F | 6.37 | pIC50 | 424.4 | nM | IC50 | J Biol Chem (2007) 282: 2494-2504 [PMID:17110371] |
| ChEMBL | Inhibition of drug-resistant Plasmodium falciparum Dd2 after 72 hrs | F | 5.41 | pEC50 | 3900 | nM | EC50 | Bioorg Med Chem Lett (2005) 15: 5247-5252 [PMID:16198563] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum Dd2 by reduced [3H]hypoxanthine uptake | F | 5.42 | pEC50 | 3800 | nM | EC50 | J Biol Chem (2007) 282: 25436-25444 [PMID:17567585] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum Dd2 assessed as inhibition of parasite growth | F | 5.42 | pEC50 | 3800 | nM | EC50 | Bioorg Med Chem Lett (2013) 23: 1022-1025 [PMID:23313245] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum Dd2 | F | 5.42 | pEC50 | 3800 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 2163-2169 [PMID:16466916] |
| ChEMBL | Inhibition of drug-sensitive Plasmodium falciparum 3D7 after 72 hrs | F | 5.54 | pEC50 | 2900 | nM | EC50 | Bioorg Med Chem Lett (2005) 15: 5247-5252 [PMID:16198563] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum 3D7 | F | 5.54 | pEC50 | 2900 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 2163-2169 [PMID:16466916] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite growth | F | 5.54 | pEC50 | 2900 | nM | EC50 | Bioorg Med Chem Lett (2013) 23: 1022-1025 [PMID:23313245] |
| ChEMBL | Antimalarial activity against Plasmodium falciparum 3D7 by reduced [3H]hypoxanthine uptake | F | 5.55 | pEC50 | 2800 | nM | EC50 | J Biol Chem (2007) 282: 25436-25444 [PMID:17567585] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum 3D7 | F | 5.81 | pEC50 | 1550 | nM | EC50 | Eur J Med Chem (2021) 224: 113722-113722 [PMID:34364164] |
| transthyretin/Transthyretin in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3194] [GtoPdb: 2851] [UniProtKB: P02766] | ||||||||
| ChEMBL | Binding affinity to wildtype TTR (unknown origin) assessed as dissociation constant by ITC analysis | B | 6.32 | pKd | 484 | nM | Kd | J Med Chem (2025) 68: 1572-1586 [PMID:39761163] |
| ChEMBL | Inhibition of acid-mediated TTR V30M mutant (unknown origin) aggregation preincubated for 30 mins followed by sodium acetate buffer at pH 5.2 addition and measured after 7 days by absorbance based turbidity assay | B | 4.74 | pKi | 18000 | nM | Ki | J Med Chem (2025) 68: 1572-1586 [PMID:39761163] |
| ChEMBL | Inhibition of transthyretin fibril formation at pH 4.4 | F | 4.27 | pIC50 | 53500 | nM | IC50 | J Med Chem (2007) 50: 5589-5599 [PMID:17948976] |
ChEMBL data shown on this page come from version 37:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]